Regeneron Pharmaceuticals, Inc.’s stock price soars to $614.79, marking a robust 3.21% increase

Regeneron Pharmaceuticals, Inc. (REGN)

614.79 USD +19.13 (+3.21%) Volume: 1.1M

Regeneron Pharmaceuticals, Inc.’s stock price is currently trading at 614.79 USD, marking a positive session change of +3.21%. Despite a considerable trading volume of 1.1M, the stock has experienced a decrease of -13.69% Year-to-Date (YTD), reflecting its volatile performance in the market.

Latest developments on Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. made headlines today with its acquisition of 23andMe, a biotech company, for $256 million. This move underscores the importance of market definition and the company’s commitment to AI-powered COPD solutions through a partnership with Viz.ai. Regeneron’s purchase of 23andMe raises questions about privacy and the future of consumer genetics services. The acquisition, including sensitive genetic data, is part of Regeneron’s strategy to scale drug development and expand its genetic data and innovation footprint. With this $256 million deal, Regeneron aims to leverage genetic data ethically and continue consumer genome services while protecting privacy.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma